Determining Risk Factors for Successful PPI Weaning

Status Terminated

Clinical Trial Summary

Gastroesophageal Reflux Disease ("GERD") can happen when stomach acid flows backward into your esophagus (tube from the mouth to the stomach), causing symptoms such as heartburn. Proton pump inhibitors (called "PPIs") are a type of medication that reduce acid in the stomach and are used to reduce the discomfort from GERD. Treatment for GERD with PPIs is recommended to last up to eight weeks; however, many people take them for longer periods. Some people are placed on PPIs (particularly in the hospital) to prevent ulcers and inflammation of the stomach, but they do not need to be on the medication long term. Previous research studies have shown that there are some risks with taking PPIs for a long time. These risks include the inability of your body to absorb some vitamins and minerals, certain infections such as pneumonia or the digestive tract infection called "C. diff," and possibly bone fractures. Therefore, it is desirable to stop taking a PPI when possible.

The purpose of this study is to use a standard approach to help patients stop taking PPIs by adopting lifestyle habits known to reduce the symptoms of GERD while they slowly reduce their PPI dose. All medications used for this study are approved by the U.S. Food and Drug Administration ("FDA"). You are being asked to take part in this study because you have been taking a PPI for longer than the recommended time, and have either a diagnosis of GERD, gastritis, or an unclear indication for being on a PPI. About 100 patients from the Mount Carmel St. Ann's Family Medicine practice will participate in this research.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Gastroesophageal Reflux

Clinical Trial Details

NCT number	NCT03226054
Study type	Interventional
Source	Mount Carmel Health System
Contact
Status	Terminated
Phase	N/A
Start date	September 1, 2016
Completion date	October 1, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05561179` - Hyaluronic Acid in Patients With Gastroesophageal Reflux Disease	N/A
Withdrawn	`NCT02213887` - Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications	Phase 4
Completed	`NCT01946971` - Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)	Phase 1/Phase 2
Recruiting	`NCT01825473` - Study of Erythromycin in GER-Associated Apnea of the Newborn	N/A
Completed	`NCT00614536` - Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period	Phase 4
Completed	`NCT00365300` - Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)	Phase 3
Completed	`NCT00284908` - Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers	Phase 1
Completed	`NCT00373997` - Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux	Phase 4
Completed	`NCT00567021` - German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms	N/A
Completed	`NCT00141960` - Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease	Phase 2/Phase 3
Completed	`NCT00215787` - Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease	N/A
Completed	`NCT00226044` - Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.	Phase 3
Completed	`NCT00291746` - Validation of RDQ Questionnaire	Phase 4
Completed	`NCT01167543` - Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease	N/A
Completed	`NCT00181805` - Natural History of Gastroesophageal Reflux (GER) in Children and Adolescents
Completed	`NCT01048840` - Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age
Terminated	`NCT01281553` - A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease	Phase 4
Completed	`NCT05486169` - Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy	N/A
Completed	`NCT04034017` - Gastroesophageal Reflux Disease Among College Students
Active, not recruiting	`NCT03015610` - Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma	Phase 3